About Cardiosense
Cardiosense is a digital health company that develops AI-powered cardiac monitoring technology to detect early signs of heart disease and facilitate personalized therapy. Their platform leverages wearable sensing technology, advanced signal processing, and deep learning to convert raw physiological data into clinical intelligence. The company’s primary medical-grade wearable monitor, CardioTag, is designed to noninvasively capture three distinct physiological signals: electrocardiogram (ECG), photoplethysmogram (PPG), and seismocardiogram (SCG). This multimodal sensor integration, combined with AI-driven digital biomarkers, provides comprehensive cardiac assessment capabilities.
Cardiosense’s initial focus is on improving heart failure management. Their CardioTag device and PCWP Analysis Software™ recently received FDA De Novo classification, enabling non-invasive estimation of Pulmonary Capillary Wedge Pressure (PCWP) at the point of care. This technology aims to provide clinicians with real-time, objective hemodynamic insights, allowing for more precise and proactive management of heart failure patients, potentially reducing hospitalizations and optimizing medical therapy. The company’s approach is to provide timely clinical decision support across various care settings, including emergency department assessment, inpatient management, discharge planning, and outpatient/at-home monitoring.
Focus Areas
Business Intelligence
| Technology | AI platform leveraging wearable sensing technology, advanced signal processing, and deep learning to convert raw physiological data into clinical intelligence. Cloud-native approach for data aggregation and analysis. |
What Physicians Need to Know
For physicians, Cardiosense offers a revolutionary approach to heart failure management by providing noninvasive, real-time insights into Pulmonary Capillary Wedge Pressure (PCWP). This allows for earlier detection of worsening conditions, more precise and proactive management of heart failure, and optimization of medication protocols. The CardioTagu2122 device is easy to use and provides rapid, accurate PCWP readings, validated against right heart catheterization. This can lead to timely clinical decision support, reduced heart failure hospitalizations, and improved long-term patient outcomes. The ability to monitor PCWP remotely also facilitates better outpatient and at-home care, detecting and treating worsening conditions before symptoms arise.
CardioSense AI, a related entity or product, mentions seamless integration with existing Electronic Medical Record (EMR) systems for AI-powered ECG interpretation. While specific integrations for Cardiosense's heart failure platform are not explicitly detailed, the focus on providing clinical intelligence and decision support suggests a need for interoperability with healthcare IT systems to maximize utility in various care settings. Data captured by the CardioTagu2122 device can be reviewed in an online dashboard, providing information to doctors previously only available within the hospital setting.
What the Web Says
Cardiosense is a medical AI company that has developed the CardioTag device, a wearable sensor for noninvasive cardiac function monitoring, and AI-powered software for estimating pulmonary capillary wedge pressure (PCWP). The CardioTag device has received FDA 510(k) clearance, and its PCWP Analysis Software has been granted De Novo classification by the FDA, indicating its novelty and low-to-moderate risk. The company aims to provide clinically actionable insights for early detection of cardiac disease, personalized therapy, and improved patient outcomes, particularly in heart failure management.
Overall: PositiveStrengths
- Noninvasive cardiac monitoring with the CardioTag device.
- Simultaneous capture of ECG, PPG, and SCG signals.
- AI algorithms for estimating cardiac parameters like PCWP.
- FDA clearance for CardioTag device.
- FDA De Novo classification for PCWP Analysis Software.
- Potential for earlier intervention and better management of heart failure.
Limitations
- Limited public reviews available on platforms like G2, Glassdoor, and Capterra.
- Reddit discussions primarily focus on other cardiac monitoring devices (e.g., KardiaMobile, CardioMems) rather than Cardiosense specifically.
- One Reddit post mentions Cardiosense in a list of 'emerging noninvasive technologies' but provides no direct reviews.
- No specific employer reviews for Cardiosense were found on Glassdoor or Indeed; general cardiology-related company reviews were found instead.
- The technology is relatively new, with FDA clearances occurring in 2025 and 2026, so long-term user experiences may not yet be widely available.
Based on reviews from: G2, Glassdoor, Capterra, Medical Economics, MedTech Dive, Diagnostic and Interventional Cardiology, Reddit, Cardiosense Company News
Last updated: 2026-10-01
Videos
News, demos, and interviews about Cardiosense.
Videos load interactively. If none appear, search YouTube for Cardiosense →
Press & Coverage
Frequently Asked Questions
Investors
Who's funded Cardiosense.
Related Companies
Perimeter Medical Imaging AI is a medical technology company dedicated to transforming cancer surgery through the use of ultra-high-resolution, real-time, advanced imaging tools. The company’s mission is to address significant unmet medical needs in cancer surgery, particularly concerning positive margins and the resulting need for re-excisions. Their proprietary technology, including the S-Series Optical Coherence Tomography […]
Veeva Systems is a global leader in cloud-based software solutions specifically designed for the life sciences industry, including pharmaceutical and biotech companies. The company’s offerings are crucial for managing various aspects of drug development, pharmaceutical manufacturing, and commercial operations. Their platforms help clients navigate complex regulatory requirements, improve operational efficiency, and accelerate the delivery of […]
The University at Buffalo (UB) is a prominent public research university and a flagship institution of the State University of New York (SUNY) system. While UB itself is a broad academic institution, the provided URL (halsted.compbio.buffalo.edu) points to a specific area within UB focused on computational biology. This division is actively engaged in healthcare AI […]
TimeDoc Health is a healthcare technology and services company that provides virtual care management solutions, primarily focusing on chronic care management (CCM), remote patient monitoring (RPM), and behavioral health integration (BHI). Their platform and services are designed to help healthcare organizations, including primary care providers, health systems, FQHCs (Federally Qualified Health Centers), and Medicare Advantage […]
Prenaital is an AI-driven healthcare company focused on revolutionizing maternal care by improving the early detection and management of high-risk pregnancies. Their AI models analyze ultrasound images to identify at-risk pregnancies, including those with abnormal fetal growth and a risk of preterm birth, with significantly higher accuracy than current clinical practices—detecting 25-50% more high-risk cases. […]
PHQ Screeners is a free, open-access resource maintained by Pfizer, providing a comprehensive suite of Patient Health Questionnaire (PHQ) and Generalized Anxiety Disorder (GAD-7) screening instruments. These tools were developed by Drs. Robert L. Spitzer, Janet B.W. Williams, and Kurt Kroenke with an educational grant from Pfizer, and are widely utilized in primary care and […]